Surveillance of Mycobacterium tuberculosis susceptibility to second-line drugs in Hong Kong, 1995-2002, after the implementation of DOTS-Plus

International Journal of Tuberculosis and Lung Disease

Volumn 8, Issue 6, 2004, Pages 760-766

  Kam, Kai Man ^a   Yip, C W ^a  

^a DEPARTMENT OF HEALTH   (Hong Kong)

Author keywords

DOTS Plus; Hong Kong; Retreatment cases; Second line anti tuberculosis drugs; Tuberculosis

Indexed keywords

AMIKACIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; OFLOXACIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATE; HEALTH PROGRAM; HONG KONG; HUMAN; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; PRIORITY JOURNAL; SHORT COURSE THERAPY; TUBERCULOSIS; TUBERCULOSIS CONTROL;

AMIKACIN; ANTI-BACTERIAL AGENTS; ANTITUBERCULAR AGENTS; COMMUNICABLE DISEASE CONTROL; CYCLOSERINE; DIRECTLY OBSERVED THERAPY; DRUG COMBINATIONS; ETHIONAMIDE; HONG KONG; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; OFLOXACIN; POPULATION SURVEILLANCE; PROGRAM EVALUATION; RECURRENCE; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 2942574537     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Loddenkemper R, Sagebiel D, Brendel A. Strategies against multidrug-resistant tuberculosis. Eur Respir J 2002; 20 (Suppl 36): 66s-77s.
2. Suàrez P G, Floyd K, Portocarrero J, et al. Feasibility and cost-effectiveness of standardized second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 2002; 359: 1980-1989.
3. Park S K, Kim C T, Song S D. Outcome of chemotherapy in 107 patients with pulmonary tuberculosis resistant to isoniazid and rifampicin. Int J Tuberc Lung Dis 1998; 2: 877-884.
4. Telzak E E, Sepkowitz K, Alpert P, et al. Multidrug-resistant tuberculosis in patients without HIV infection. N Engl J Med 1995; 333: 907-911.
5. Espinal M A, Laserson K, Camacho M, et al. Determinants of drug-resistant tuberculosis: analysis of 11 countries. Int J Tuberc Lung Dis 2001; 5: 887-893.
6. Kam K M, Yip C W. Surveillance of Mycobacterium tuberculosis drug resistance in Hong Kong, 1986-1999, after the implementation of Directly Observed Treatment. Int J Tuberc Lung Dis 2001; 5: 815-823.
7. Kent P T, Kubica G P. A Guide for the Level III Laboratory. Atlanta, GA: Centers for Disease Control, 1985.
8. Medical Research Council. Cooperative controlled trial of a standard regimen of streptomycin, PAS and isoniazid and three alternative regimens of chemotherapy in Britain. Tubercle 1973; 54: 99-129.
9. World Health Organization. Guidelines for drug susceptibility testing for second-line anti-tuberculosis drugs for DOT-plus. WHO/CDS/TB/2001.288. Geneva, Switzerland: WHO, 2001.
10. Department of Health and Hospital Authority, Hong Kong. Chemotherapy of tuberculosis in Hong Kong: a consensus statement The Tuberculosis Control Coordinating Committee (Department of Health) and the Tuberculosis Subcommittee of the Coordinating Committee in Internal Medicine (Hospital Authority), Hong Kong. Hong Kong Med J 1998; 4: 315-320.
11. Abate G, Miorner H, Ahmed O, Hoffner S E. Drug resistance in Mycobacterium tuberculosis strains isolated from re-treatment cases of pulmonary tuberculosis in Ethiopia: susceptibility of first-line and alternative drugs. Int J Tuberc Lung Dis 1998; 2: 580-584.
12. Fattorini L, Iona E, Ricci M L, et al. Activity of 16 antimicrobial agents against drug-resistant strains of Mycobacterium tuberculosis. Microb Drug Resist 1999; 5: 265-270.
13. World Health Organization. Anti-Tuberculosis Drug Resistance in the world. Report No. 2. Prevalence and Trends. WHO/ CDC/TB/2000.278. Geneva, Switzerland: WHO, 2000.
14. Pfyffer G E, Bonato D A, Ebrahimzadeh A, et al. Multicenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer anti-microbial drugs by using the radiometric bactec 460 technique and the proportion method with solid media. J Clin Microbiol 1999; 37: 3179-3186.
15. Hong Kong Tuberculosis and Chest Services. Annual Report. Department of Health. Hong Kong SAR, China: Hong Kong SAR Government, 2001.
16. Avendano M, Goldstein R S. Multidrug-resistant tuberculosis: long term follow-up of 40 non-HIV-infected patients. Can Respir J 2000; 7: 383-389.
17. Maranetra K N. Quinolone and multidrug-resistant tuberculosis. Chemotherapy 1999; 45 (Suppl 2): 12-18.
18. Yew W W, Chan C K, Chau C H, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 2000; 117: 744-751.
19. Singla R, Gupta S, Gupta R, Arora V K. Efficacy and safety of sparfloxacin in combination with kanamycin and ethionamide in multidrug-resistant pulmonary tuberculosis patients: preliminary results. Int J Tuberc Lung Dis 2001; 5: 559-563.
20. Berning S E. The role of fluoroquinolones in tuberculosis today. Drugs 2001; 61: 9-18.
21. Quy H T W, Lan N T N, Borgdorff M, et al. Drug resistance among failure and relapse cases of tuberculosis: is the standard regimen adequate? Int J Tuberc Lung Dis 2003; 7: 631-636.
22. Espinal, M A. Time to abandon the standard retreatment regimen with first-line drugs for failures of standard treatment. Int J Tuberc Lung Dis 2003; 7: 607-608.